menu
    • menu
    [{"orgOrder":0,"company":"InSysBio","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"GEN1042","moa":"CD40L receptor (CD40)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"InSysBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSysBio \/ Genmab","highestDevelopmentStatusID":"7","companyTruncated":"InSysBio \/ Genmab"},{"orgOrder":0,"company":"InSysBio","sponsor":"Discoveric Bio","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"NIDB-3101","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"InSysBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InSysBio \/ Discoveric Bio","highestDevelopmentStatusID":"4","companyTruncated":"InSysBio \/ Discoveric Bio"},{"orgOrder":0,"company":"InSysBio","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"RUSSIA","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"BGB-B2033","moa":"GPC3\/4-1BB","graph1":"Oncology","graph2":"Phase I","graph3":"InSysBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"InSysBio \/ BeOne Medicines","highestDevelopmentStatusID":"6","companyTruncated":"InSysBio \/ BeOne Medicines"}]

    Find Clinical Drug Pipeline Developments & Deals by InSysBio

    Menu

    InSysBio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            InSysBio

                            Russia arrow
                            Neuroscience
                            Not Confirmed

                            InSysBio

                            Russia arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BGB-B2033

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : BeOne Medicines

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            InSysBio Announces Collaboration with BeOne Medicines

                            Details : The collaboration aims to advance oncology research through the development of BGB-B2033, an unconjugated antibody targeting GPC3/4-1BB.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 29, 2025

                            Lead Product(s) : BGB-B2033

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : BeOne Medicines

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            InSysBio

                            Russia arrow
                            Neuroscience
                            Not Confirmed

                            InSysBio

                            Russia arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NIDB-3101

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Discoveric Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            InSysBio Announces Its Collaboration with Discoveric Bio Alpha

                            Details : The collaboration aims to advance the NIDB-3101, which is being evaluated for the treatment of Alzheimer’s disease.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 19, 2025

                            Lead Product(s) : NIDB-3101

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Discoveric Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            InSysBio

                            Russia arrow
                            Neuroscience
                            Not Confirmed

                            InSysBio

                            Russia arrow
                            Neuroscience
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GEN1042

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Genmab

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            InSys Bio Announces Its Collaboration with Genmab

                            Details : Genmab together with BioNTech, has begun clinical development of an investigational therapy, GEN1042 (DuoBody®-CD40x4-1BB), for solid tumors. GEN1042 is a novel bispecific agonistic antibody targeting CD40 and 4-1BB for priming and activation of tumor-s...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            September 23, 2020

                            Lead Product(s) : GEN1042

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Genmab

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth